CLSI C63
Laboratory Support for Pain Management Programs
CLSI C63 provides essential guidance for laboratory toxicology testing in pain management programs. It covers specimen collection, testing methodologies, and result interpretation. Designed for laboratorians, healthcare providers, pharmacists, and risk managers, this guideline supports accurate and reliable testing to enhance patient care and ensure effective monitoring of pain management treatments.
This reaffirmed document has been reviewed and confirmed as suitable to remain published without revision to content, as of January 2023.
{{FormatPrice(currentPrice)}}
Free
{{FormatPrice(nonMemberPrice)}} List PriceClinical and Laboratory Standards Institute guideline C63—Laboratory Support for Pain Management Programs provides recommendations for medical laboratory toxicology-based testing services in support of the care and treatment of persons in pain management programs. This guideline discusses specimen types and collection, testing methodologies, and results reporting and interpretation. The intended users of this guideline include medical laboratory scientists and personnel, medical technologists, hospital administrators, physician office personnel, risk managers, pharmacists, and health care providers tasked with implementing pain management testing for their institutions or networks.
This guideline provides recommendations for laboratory support for pain management clinics and services, including guidance on specimen types and collection, testing methodologies, results reporting, and interpretation. To assist in results interpretation, this guideline includes several tables listing expected metabolites for commonly encountered drugs.
The intended users of this guideline include medical laboratory scientists and personnel, hospital administrators, physician office personnel, risk managers, pharmacists, and health care providers tasked with establishing pain management testing for their institutions or networks.
This guideline does not discuss in detail the pathophysiology or biochemistry of chronic pain, nor does it include information on dosing or prescribing of pain management drugs.
Clinical and Laboratory Standards Institute guideline C63—Laboratory Support for Pain Management Programs provides recommendations for medical laboratory toxicology-based testing services in support of the care and treatment of persons in pain management programs. This guideline discusses specimen types and collection, testing methodologies, and results reporting and interpretation. The intended users of this guideline include medical laboratory scientists and personnel, medical technologists, hospital administrators, physician office personnel, risk managers, pharmacists, and health care providers tasked with implementing pain management testing for their institutions or networks.
This guideline provides recommendations for laboratory support for pain management clinics and services, including guidance on specimen types and collection, testing methodologies, results reporting, and interpretation. To assist in results interpretation, this guideline includes several tables listing expected metabolites for commonly encountered drugs.
The intended users of this guideline include medical laboratory scientists and personnel, hospital administrators, physician office personnel, risk managers, pharmacists, and health care providers tasked with establishing pain management testing for their institutions or networks.
This guideline does not discuss in detail the pathophysiology or biochemistry of chronic pain, nor does it include information on dosing or prescribing of pain management drugs.